Suspension of trading

Highlights Unity Biotechnology, Inc.

Stocks

UBX

US91381U2006

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 20:00:08 01/10/2025 BST			5-day change	1st Jan Change
0.0561 ^USD	+0.36%		-.--%	-

21/07/25	Unity Biotechnology, Inc. announced that it has received $0.000001 million in funding	CI
11/07/25	Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from S&P TMI Index	CI

Highlights

05/05/25	UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates	CI
23/04/25	UNITY Biotechnology, Inc. Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME	CI
22/04/25	Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
24/03/25	Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular Edema	CI
07/03/25	Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
07/03/25	Unity Biotechnology, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2024	CI
04/11/24	Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
06/08/24	Unity Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
22/07/24	UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy Officer	CI
14/05/24	Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/04/24	Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	CI
15/04/24	Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
15/04/24	Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
06/02/24	Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss	CI
12/12/23	Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME	CI
13/11/23	Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
27/09/23	UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration	CI
08/08/23	Unity Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
21/06/23	Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema	CI
09/05/23	Unity Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
24/04/23	Unity Biotechnology, Inc. Announces Positive 48-Week Results from Phase 2 Bold Study of UBX1325 in Patients with Diabetic Macular Edema	CI
27/03/23	Unity Biotechnology, Inc. Announces Results from Part A of the Phase 2 Envision Study	CI
15/03/23	Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
15/03/23	Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
08/11/22	Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI